Copenhagen, Denmark

Michiel Onne Elema



Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michiel Onne Elema: Innovator in Controlled Agglomeration Technology

Introduction: Michiel Onne Elema is a prominent inventor based in Copenhagen, Denmark, known for his innovative contributions to pharmaceutical technology. With a focus on enhancing the solubility of active substances in drug formulations, Elema's work is pivotal in improving the efficacy of various pharmaceutical compositions.

Latest Patents: Michiel Elema holds a patent for a groundbreaking process titled "Controlled agglomeration." This method enables the preparation of particulate materials with controlled particle size growth, which is particularly beneficial for substances that possess low aqueous solubility or are prone to chemical degradation. The patented process involves spraying a liquid carrier composition onto a solid material while maintaining conditions that prevent the carrier from melting. This innovative approach enhances the formulation of pharmaceutical compositions, ensuring better delivery and stability of therapeutically active substances.

Career Highlights: Elema's current association is with Lifecycle Pharma A/S, a company dedicated to advancing pharmaceutical innovation. His expertise in controlled agglomeration showcases his commitment to addressing challenges faced in drug formulation. With one patent to his name, Elema's work is recognized as a significant step forward in pharmaceutical technology.

Collaborations: Throughout his career, Elema has collaborated with notable colleagues, including Per Holm and Anders Buur. These partnerships have facilitated the sharing of knowledge and expertise, contributing to the advancement of innovative solutions within the pharmaceutical sector.

Conclusion: Michiel Onne Elema's inventive spirit and technical expertise in controlled agglomeration underline his importance in the field of pharmaceutical innovations. His contributions not only demonstrate the potential for improved drug formulations but also inspire future advancements in the industry. As he continues to work with Lifecycle Pharma A/S, the impact of his innovations is expected to resonate throughout the pharmaceutical landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…